Fc Receptors for IgG (Fc gamma Rs) on Human Monocytes and Macrophages Are Not Infectivity Receptors for Human Immunodeficiency Virus Type 1 (HIV-1): Studies Using Bispecific Antibodies to Target HIV-1 to Various Myeloid Cell Surface Molecules, including the Fc Gamma R. by Connor, R I et al.
Dartmouth College 
Dartmouth Digital Commons 
Open Dartmouth: Peer-reviewed articles by 
Dartmouth faculty Faculty Work 
11-1991 
Fc Receptors for IgG (Fc gamma Rs) on Human Monocytes and 
Macrophages Are Not Infectivity Receptors for Human 
Immunodeficiency Virus Type 1 (HIV-1): Studies Using Bispecific 
Antibodies to Target HIV-1 to Various Myeloid Cell Surface 
Molecules, including the Fc Gamma R. 
R I. Connor 
Dartmouth College 
N B. Dinces 
Dartmouth College 
A L. Howell 
Dartmouth College 
J L. Romet-Lemonne 
Immuno-Designed Molecules 
J L. Pasquali 
Laboratorie d'immunopathologie Clinique Medicale 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa 
 Part of the Infectious Disease Commons, and the Medical Microbiology Commons 
Dartmouth Digital Commons Citation 
Connor, R I.; Dinces, N B.; Howell, A L.; Romet-Lemonne, J L.; Pasquali, J L.; and Fanger, M W., "Fc 
Receptors for IgG (Fc gamma Rs) on Human Monocytes and Macrophages Are Not Infectivity Receptors 
for Human Immunodeficiency Virus Type 1 (HIV-1): Studies Using Bispecific Antibodies to Target HIV-1 to 
Various Myeloid Cell Surface Molecules, including the Fc Gamma R." (1991). Open Dartmouth: Peer-
reviewed articles by Dartmouth faculty. 1068. 
https://digitalcommons.dartmouth.edu/facoa/1068 
This Article is brought to you for free and open access by the Faculty Work at Dartmouth Digital Commons. It has 
been accepted for inclusion in Open Dartmouth: Peer-reviewed articles by Dartmouth faculty by an authorized 
administrator of Dartmouth Digital Commons. For more information, please contact 
dartmouthdigitalcommons@groups.dartmouth.edu. 
Authors 
R I. Connor, N B. Dinces, A L. Howell, J L. Romet-Lemonne, J L. Pasquali, and M W. Fanger 
This article is available at Dartmouth Digital Commons: https://digitalcommons.dartmouth.edu/facoa/1068 
Proc. NatI. Acad. Sci. USA
Vol. 88, pp. 9593-9597, November 1991
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Fc receptors for IgG (FcyRs) on human monocytes and macrophages
are not infectivity receptors for human immunodeficiency virus type
1 (HIV-1): Studies using bispecific antibodies to target HIV-1 to
various myeloid cell surface molecules, including the FcyR
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ABSTRACT FcyRs (FcyRI, FcyRI1, and FcyRM) are
highly expressed on human mononuclear phagocytes and func-
tion in the clearance of immune complexes and opsonized
pathogens. We have examined the role of FcyR in mediating
antibody-dependent clearance of HIV-1 by human monocytes
and monocyte-derived macrophages by using bispecific anti-
bodies (BsAbs) to independently target the virus to FcyRI,
FcyRll, or FcyRI. Virus production was markedly reduced
in monocytes cultured with strain HIV-lmB opsonized with
BsAbs that target the virus to either FcyRI or FcyRll com-
pared to monocytes cultured with virus in the absence ofBsAbs
or in the presence of BsAbs that target the virus to non-FcyR
surface antigens (CD33 and HLA-A,B,C). These results were
confirmed using the monotropic isolate HIV-1.RFL Interaction
of HIV-laum with FcyRI or FcyRiH on human monocytes and
FcyRI, FcyRil, or FcyRiII on monocyte-derived macro-
phages resulted in markedly reduced levels of virus production
in these cultures. Moreover, HIV-1 infection of monocytes and
monocyte-derived macrophages was completely blocked by
anti-CD4 monoclonal antibodies, indicating that interaction
with CD4 is required for infectivity even under conditions of
antibody-mediated binding of HIV-1 to FcyR. Thus, we pro-
pose that highly opsonized HIV-1 initiates high-affinity multi-
valent interactions with FcyR that trigger endocytosis and
intracellular degradation of the antibody-virus complex. At
lower levels of antibody opsonization, there are too few inter-
actions with FcyR to initiate endocytosis and intracellular
degradation of the antibody-virus complex, but there are
enough interactions to stabilize the virus at the cell surface,
allowing antibody-dependent enhancement of HIV-1 infection
through high-affinity CD4 interactions. However, our results
suggest that interaction of highly opsonized HIV-1 with FcyRs
through BsAbs may reduce viral infectivity through FcyR-
mediated cytotoxic mechanisms and, therefore, that BsAbs
offer promise as therapeutic reagents in HIV-1 infections.
Infection of monocytes/macrophages with HIV-1 occurs
through the direct interaction of the viral envelope glycopro-
tein gp120 with the CD4 receptor (1). Several studies have
suggested that infectivity may also occur through the inter-
action of antibody-opsonized HIV-1 with one or more of the
FcyRs on mononuclear phagocytes (2-6), termed antibody-
dependent enhancement (ADE). In contrast, others have
reported that infection of human macrophages in the pres-
ence of enhancing antibodies (7, 8) and HIV-antibody com-
plexes (2) is dependent on gpl2O-CD4 binding (7-9). These
findings suggest that several critical factors may be involved
in determining HIV infectivity mediated through interactions
involving the FcyR, including the target cell population, the
source and isolate of HIV-1, the specificity and neutralizing
capacity ofanti-HIV-1 antibodies, and the class ofFcyR. The
present study used bispecific antibodies (BsAbs) composed
of Fab fragments of an anti-FcyR monoclonal antibody
(mAb) covalently linked to a Fab anti-HIV mAb to selec-
tively target HIV-1 to specific FcyRs, allowing direct inde-
pendent analysis of the role of FcyRI, FcyRII, and FcyRIII
in infection. HIV-1 complexed with BsAb served as a model
for antibody opsonization and was used to evaluate the
interaction with FcyRs on selected target cells.
Our findings indicate that interaction with FcyRI and
FcyRII on monocytes and FcyRI, FcyRII, and FcyRIII on
macrophages decreases infection with HIV-1 under condi-
tions consistent with high antibody opsonization. Interac-
tions with HLA class I or CD33 antigen did not decrease
infection with HIV-1. Moreover, infection was completely
blocked by pretreatment of the cells with anti-CD4 mAb,
indicating that viral interaction with CD4 is required for
infectivity, even under conditions ofantibody-mediated bind-
ing to FcyR.
MATERIALS AND METHODS
Effector Cells. Monocytes were purified from normal vol-
unteers as described (10).
IRV Preparations. Strain HIV-1JRFL (11) was cultured in
phytohemagglutinin-stimulated peripheral blood mononu-
clear cells and titered by end-point dilution to determine the
50% tissue-culture infectious dose (TCID50). Strain HIV-lii1B
was obtained from cultures of infected H9 cells and was
similarly titered.
Antibodies and Antibody Fragments. The derivation and
properties of the mouse mAbs specific to each of the FcyR
have been reported. mAb 32.2 (IgG1) recognizes FcyRI (12),
mAb IV.3 (IgG2b) recognizes FcyRII (13, 14), and mAb 3G8
(IgG1) recognizes FcyRIII (15). The mouse mAb 251 (IgG1)
specific for CD33 (16) and mAb W6/32 (IgG2a), which
recognizes a common epitope ofHLA-A, B, C, were used as
controls. mAb gp1123, a mouse IgG1, recognizes an epitope
comprising residues 302 to 324 in the V3 region of HIV
glycoprotein gp120 (17). mAb gpI,11,2, a mouse IgG1 (17),
Abbreviations: FcyR, Fc receptor for IgG; HIV-1, human immun-
odeficiency virus type I; M/M, monocyte-derived macrophage;
BsAb, bispecific antibody; mAb, monoclonal antibody; ADE, anti-
body-dependent enhancement; TCIDm, 50o tissue-culture infec-
tious dose; TNB, thiobis(2-nitrobenzoic acid); SATA, N-succin-
imidyl-S-acetylthioacetate.
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recognizes a 23-residue epitope at the highly conserved gpl20
N-terminal region.
IgG mAbs were produced in hollow-fiber cartridges (Am-
icon) and purified by HPLC on a DEAE 5PQ column (Wa-
ters). mAbs gpI,11,2 and W6/32 were purified from ascites
fluid by similar methods. mAb gpIII23 was purified from
ascites fluid by gel filtration and affinity chromatography
using a Bio-Sil TSK 250 HPLC column (Bio-Rad) and Protein
A-agarose (Sigma). F(ab')2 fragments of the IgG1 and IgG2a
mAbs were made by pepsin digestion (18) and purified by gel
filtration using a TSK 3000 HPLC column (TosoHaas, Phil-
adelphia, PA). Fab fragments of the IgG2b mAb IV.3 were
obtained using immobilized papain and separated using pro-
tein A (Pierce).
BsAb Formation. F(ab')2 fragments of mAbs 32.2, 3G8,
251, and W6/32 were reduced to Fab' fragments by 10 mM
mercaptoethylamine hydrochloride (Sigma) under nitrogen
(30 min, 370C). 5,5'-Dithiobis(2-nitrobenzoic acid) (Sigma)
was added to 20 mM, and the mixture was incubated under
nitrogen (3 hr, 250C). The Fab-thiobis(2-nitrobenzoic acid)
(TNB) was isolated on a TSK 3000 column. F(ab')2 fragments
of mAbs gpIII23 and gpI,11,2 were reduced to Fab'-SH with 10
mM mercaptoethylamine and the Fab' fragments were iso-
lated using a Sephadex G-25 column (Pharmacia). Equimolar
amounts of the appropriate Fab-TNB and Fab'-SH antibod-
ies were mixed under nitrogen and incubated at 22°C for 18
hr. The Fab x Fab BsAb was purified from the mixture by
HPLC gel filtration chromatography on a TSK 3000 column
and sterilized by 0.2-,m filtration. The protein concentration
of each conjugate was- determined by BCA assay using a
Micro BCA kit (Pierce).
To prepare the gpI,11,2 Fab x IV.3 Fab conjugate, gpI,11,2
F(ab')2 was reduced to Fab' using mercaptoethylamine, and
TNB groups were introduced. IV.3 Fab was treated with
N-succinimidyl-S-acetylthioacetate (SATA) in the presence
of 1 mM EDTA, yielding two or three SATA groups per Fab
fragment. Excess SATA was removed on Sephadex G-25.
IV.3 Fab-SATA was then mixed with a 1.5 molar excess of
gpI,11,2 Fab'-TNB (1.5 mol of TNB per mol of SATA) under
nitrogen and incubated at 22°C for 18 hr. The Fab x Fab
cross-linked conjugate was purified as described above and
sterilized by 0.2-,um filtration.
Reactivity of BsAb. Binding of the anti-gpl20 end of the
BsAb was demonstrated by ELISA. Recombinant gpl20
(American Biotechnologies, Columbia, MD) was added to a
96-well plate at 0.2 ug per well in phosphate-buffered saline
(PBS). After incubation at 37°C for 4 hr. washing, and
blocking with bovine serum albumin [5% (wt/vol)], antibody
stocks (100,ul per well) at concentrations from 10 ng/ml to 10
,ug/ml were added in PBS/1% bovine serum albumin (PBA),
and the plate was incubated 2 hr at 37°C. After thorough
washing, goat anti-mouse immunoglobulin conjugated to
alkaline phosphatase diluted 1:250 was added (75 ,ul per well).
After an 18-hr incubation at 22°C, the plate was washed
thoroughly and developed using p-nitrophenyl phosphate
disodium (Sigma) (60 ul per well from a stock of 2 mg/ml).
The binding of the effector cell end of the BsAb was
verified by flow cytometry. Approximately 1 x 106 buffy-
coat cells from normal peripheral blood were incubated for 90
min at 4°C with BsAb or control antibody (10 ng/ml to 100
,ug/ml) in presence of human IgG (4 mg/ml), washed three
times in PBA, and treated for a further 90 min with fluores-
cein isothiocyanate-conjugated goat anti-mouse IgG/F(ab')2
(Caltag, South San Francisco, CA). After three washes, the
cells were fixed in 1% paraformaldehyde. The percent of
positively stained cells and the mean fluorescence intensity
values were determined using an Ortho 50H cytofluorograph.
Radiolabeled Virus Preparation. HIV-111IB (5 X 104 TCID50)
was inoculated into cultures of phytohemagglutinin-
stimulated peripheral blood mononuclear cells, and after
72-96 hr, supernatants from these cultures were added to
fresh phytohemagglutinin-stimulated peripheral blood mono-
nuclear cells. After 24 hr, the cells were washed and labeled
with [35S]methionine and [35S]cysteine (DuPont) in methio-
nine- and cysteine-free medium for 24 hr. Supernatants from
the labeled cultures were precleared at 3000 x g at 4TC for 20
min and centrifuged at 100,000 x g for 60 min at 40C, and
radioactivity in the concentrated virus pellets was measured
in a liquid scintillation counter.
Binding of Labeled HIV-1 to Human Monocyte FcyRs.
[35S]HIV-1 (150 x 103 cpm) was incubated for 15 min at 370C
with BsAb (10 ,ug/ml) or with medium alone. The individual
mixtures were cooled for 15 min on ice and added to 1 x 106
monocytes. To control for the binding of [35S]HIV-1 to CD4,
monocytes were pretreated for 1 hr at 4TC with the anti-CD4
mAb Leu3a (Becton Dickinson) at saturating concentrations.
Binding of [35S]HIV-1 in the presence or absence ofBsAb was
carried out at 40C for 1 hr. The cells were then washed
extensively to remove unbound virus and lysed with 0.5 ml of
1% SDS, and the amount ofcell-bound HIV-1 was determined
by scintillation counting.
Infectivity Assays. Anti-FcyR x anti-HIV or control BsAbs
were incubated for 30 min at 37°C with 50 TCID50 of either
HIV-1I1IB or HIV-lJRFL. Monocytes were then incubated
with these virus-antibody preparations at 37°C for 4 hr,
washed twice, and cultured in 24-well plates at 1 x 106 cells
per well. Samples of culture supernatants were taken on day
0 and fresh medium was added on day 3 of culture. HIV-1
production was determined at regular intervals by measuring
p24 antigen levels in culture supernatants (Abbott). In par-
allel experiments, monocytes from the same donor were
similarly studied after pretreatment for 1 hr at 4°C with mAb
Leu3a to block CD4 prior to infection. Cultures of Leu3a-
treated and control monocytes were evaluated for HIV-1
production at paired time points, and the data are expressed
as pg of p24 based on p24 standards.
Monocyte-Derived Macrophages. Freshly isolated mono-
cytes were cultured for 7 days in RPMI 1640 medium con-
taining 10% (vol/vol) fetal calf serum, penicillin (100 units/
ml), streptomycin (100 ,ug/ml), and 200 mM L-glutamine,
yielding >99%o monocyte-derived macrophages (M/Ms) as
determined by adherence, histologic staining, and indirect
immunofluorescent staining for expression of Fc'yRI,
Fc'yRII, FcyRIII, and CD14. Prior to infection, macrophages
were treated for 1 hr at 4°C with medium alone or with Leu3a
(12.5 ,ug/ml) to block CD4. Anti-FcyR x anti-HIV or control
BsAbs were incubated for 30 min at 37°C with 50 TCID50 of
HIV-1JRFL, and these preparations were incubated with
control or Leu3a-treated M/Ms for 4 hr at 37°C, washed
twice, and cultured in 24-well plates at 1 x 106 cells per well.
HIV-1 production was then measured on the days shown.
RESULTS
Binding of BsAbs to Monocytes. As reported (3), FcyRI and
FcyRII are highly expressed on monocytes and M/Ms,
whereas FcyRIII is expressed at low levels on monocytes and
high levels on M/Ms. BsAbs containing Fab fragments of
mAbs 32.2, IV.3, and 3G8 linked to Fab anti-HIV-1 mAb
(gpIII23 or gpI,11,2) reacted with monocytes to the same extent
as the unconjugated Fab anti-FcyR mAbs, confirming both
the specificity and binding capacity of these BsAbs (Table 1).
The ability of BsAbs to link radiolabeled virus to mono-
cytes was then examined. To prevent binding of HIV-1
directly to CD4, these studies were performed in the presence
of saturating concentrations of Leu3a, an anti-CD4 mAb.
High levels of HIV-1 binding to monocytes were observed
with BsAbs that directed HIV-1 to FcyRI, FcyRII, CD33, or
HLA-A,B,C; whereas low levels of binding were seen using
BsAbs that directed the virus to Fc-yRIII (Fig. 1). These
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Table 1. BsAb binding to monocyte FcyR
% positive cells
mAb x mAb x
Receptor mAb Fab Fab gp1123 Fab gpI,11,2
FcyRI 32.2 98 97 96
FcyRII IV.3 98 99 99
FcyRIII 3G8 20 27 26
HLA-A,B,C W6/32 100 100 100
CD33 251 99 99 98
Fab fragments of mAbs to FcyRI (32.2), FcyRII (IV.3), FcyRIII
(3G8), HLA-A,B,C (W6/32), and CD33 (251) and BsAbs consisting
of these Fab fragments coupled to Fab fragments of anti-gp120 mAb
(gp01123 or gpI,11,2) were evaluated for binding to human monocytes
using flow cytometry. Results shown are from a representative
experiment.
results are consistent with the pattern of FcyR, CD33, and
HLA class I expression on monocytes (3) and confirm the
ability of BsAbs to mediate interaction between HIV-1 and
monocyte FcyR.
Infection of Human Monocytes with HIV-1rns in the Pres-
ence of BsAbs. BsAbs containing Fab fragments of mAb
gp1123 were initially used to selectively target HIV-1 to
FcyRI, FcyRII, FcyRIII, or CD33. Control cultures infected
with HIV-1IIIB produced p24, which was first detected on day
16 of culture (Fig. 2a). However, monocytes infected in the
presence of BsAbs that target HIV-1 to FcyRI, FcyRII, or
FcyRIII showed very little p24 production throughout the
culture period. Virus production from monocytes infected in
the presence of anti-CD33 x Fab gp1123 BsAbs was similar
to, or greater than, that seen in control cultures (Fig. 2a).
Pretreatment with Leu3a completely blocked virus produc-
tion in cultures infected in the absence or in the presence of
any of the BsAbs (Fig. 2b), suggesting that interaction with
CD4 was necessary for infection.
Effect of BsAb on FcyR-Mediated Infection with a Mono-
tropic HIV-1 Isolate. That HIV-1 infection of monocytes may
be inhibited by interaction of antibody-coated virus with
surface FcyR was further examined using the monotropic
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FIG. 1. Binding of HIV-1 to monocytes mediated by BsAbs.
BsAb-opsonized and 35S-labeled HIV-1IIIB was incubated with
monocytes to measure binding of opsonized virus. Binding was
measured in the presence ofmAb Leu3a to block interaction of virus
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FIG. 2. Infection of human monocytes mediated through inter-
action with FcyRs. Monocytes were incubated with HIV-1IIIB in the
presence of anti-Fc'yR x gp1123 (20 ,g/ml) or control BsAbs
containing gp1123 (20 ,.g/ml) (a) or were pretreated with mAb Leu3a
prior to incubation with BsAbs (b). HIV-1 production was deter-
mined by measuring p24 antigen in culture supernatants at designated
time points. The BsAbs used are indicated.
BsAbs were constructed using Fab fragments of gpI,11,2,
which binds a conserved region ofgpl20, covalently linked to
Fab fragments ofanti-FcyR or control mAbs. Compared with
monocytes incubated with HIV-1JRFL in the absence ofBsAb
or in the presence of BsAbs that target the virus to CD33 or
HLA-A,B,C (Fig. 3a), significantly less p24 was measured in
monocyte cultures incubated in the presence of BsAbs (20
,ug/ml) that target HIV-1 to either FcyRI or to FcyRII. When
lower concentrations ofanti-FcyR x anti-HIV-1 BsAbs were
used (0.4 and 2 ,g/ml), p24 production was comparable to
that seen in control cultures. Infectivity in the presence of all
BsAbs was completely blocked by Leu3a (Fig. 3b), support-
ing our previous observation that binding ofopsonized HIV-1
to FcyR or other surface molecules is not sufficient for
infectivity in the absence of CD4 interaction.
FcyRl-Mediated Infection of M/Ms. Variable decreases
in p24 levels were measured in independent experiments after
virus interaction with FcyRIII on monocytes (Table 2) and
may relate to the low levels of FcyRIII expressed by periph-
eral blood monocytes. Therefore, we examined the effect of
HIV-1 interaction with FcyRI, FcyRII, or FcyRIII on M/Ms,
since these cells have significant FcyRIII expression (19).
Virus production from M/Ms infected with HIV-1IIIB was
observed in control cultures and in cultures infected in the
presence of anti-HLA-A,B,C x anti-HIV-1 BsAbs (Fig. 4a).
Much lower levels of p24 were measured in M/M cultures
infected in the presence of anti-FcyR x anti-HIV-1 BsAbs
and, of particular interest, in the presence of BsAbs that
target to FcyRIII. This finding was confirmed in similar
experiments using the monotropic isolate HIV-1JRFL (data
not shown). In all cases, infection with either HIV-1IIIB (Fig.
4b) or HIV-lJRFL (data not shown) was completely blocked
by pretreatment of the cells with Leu3a.
DISCUSSION
FcyRs expressed on human myeloid cells function primarily
as cytotoxic trigger molecules in the extracellular lysis of
Immunology: Connor et al.
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FIG. 3. FcyR-mediated infection of human monocytes with
HIV-lJ"rL. Monocytes were incubated with the monotropic isolate
HIV-lJRFL opsonized with BsAbs made using mAb gpI,11,2. Mono-
cytes were incubated with virus in the absence (a) or presence (b) of
Leu3a. Virus production was determined by measuring p24 antigen
in culture supernatants on day 7. Bars indicate amount of p24
produced after treatment with different BsAbs.
antibody-coated targets and the uptake and degradation of
immune complexes and opsonized pathogens (3). In virus
infections, including HIV-1 (20, 21), increasing anti-viral
antibody titers are usually associated with a decline in the
viral burden. However, the process of FcyR-mediated bind-
ing can also be exploited by certain pathogens to facilitate
entry into FcyR-bearing cells. ADE of infection has been
described for a number of viruses including HIV-1 (22). ADE
of HIV-1 infection is thought to occur through interaction of
HIV-1 with complement-fixing antibodies and subsequent
binding to cell surface complement receptors (23, 24) or
through interaction of HIV-1 with FcyR in the presence of
subneutralizing concentrations ofHIV-1 antibody (4, 5, 7-9).
The present studies were undertaken to systematically
evaluate whether antibody-mediated binding to each class of
FcyR on human monocytes/macrophages results in differ-
ential infection by HIV-1. BsAbs allowed independent anal-
ysis of the role of each FcyR in mediating infectivity.
Although significantly increased levels of virus binding oc-
curred in the presence of anti-FcyR, anti-HLA, and anti-
Table 2. FcyRIII-mediated infectivity using monocytes from
various donors
p24, pg/ml
Donor Control 0.4 2.0 20
1 >1000 788 608 446
2 >1000 >1000 966 712
3 662 731 656 646
4 701 832 711 322
5 810 763 333 154
Monocytes from five donors were incubated with HIV-1lnwL in the
absence (control) or presence ofFab 3G8 x Fab gpI,1l,2 BsAbs at 20,
2, or 0.4,g/ml, which target HIV-1 to FcyRIII. Levels ofp24 antigen
in culture supernatants of infected monocytes were determined on
day 7 after infection.
FIG. 4. Fc'yR-mediated infection of M/Ms. M/Ms were incu-
bated with BsAb-opsonized HIV-1IiIB in the absence (a) or presence
(b) of Leu3a. Levels of p24 antigen in the supernatants were
determined at the times indicated. The BsAbs used are indicated.
CD33 BsAbs (when compared to Fab fragments of these
mAbs alone), infection ofmonocytes with HIV-1IIJB occurred
only in the presence of BsAbs that target non-FcyR surface
antigens. Thus, interaction of opsonized virus with FcyR on
human monocytes appeared to inhibit infection with HIV-1.
Interaction of HIV-1 with other surface antigens either had
no effect on infectivity or resulted in ADE.
We also examined FcyR-mediated infectivity using the
monotropic isolate HIV-1jRFL and utilized BsAb-containing
Fab fragments of another anti-HIV-1 mAb, gpI,11,2. Although
the Fab fragment of this mAb caused partial inhibition of
subsequent p24 production, more appropriate controls were
used including both anti-CD33 x anti-HIV-1 and anti-HLA
class I x anti-HIV-1 BsAbs, neither of which inhibited HIV-
1jRFL infectivity. Consistent with our findings for HIV-1IIIB,
targeting ofHIV-1jRFL to Fc'yRI and FcyRII by using BsAbs (20
pug/ml) caused a significant decrease in p24 production.
Since one study (5) has reported that FcyRIII on human
macrophages plays a key role in ADE of HIV-1 infection and
that infection was independent of interaction with CD4, we
evaluated the role of FcyRIII in infection using M/Ms that
express high levels of this receptor. HIV-1 directly targeted
to FcyRIII using BsAbs (Fab 3G8 x Fab gpIII23 or Fab 3G8
x Fab gpI,11,2) resulted in decreased HIV-1 infection. More-
over, this infection was completely blocked by Leu3a, indi-
cating that, under these conditions, CD4 is required for
infection even in the presence of antibodies. Compelling
evidence from several recent studies (7-9) supports this
conclusion. Another report (6), also suggesting that HIV-1
infectivity may occur through a CD4-independent FcR-
mediated pathway, involved human fibroblasts coinfected
with cytomeglovirus. These cells express cytomeglovirus-
encoded Fc receptors that are distinct from human FcyR,
making further interpretation of those results difficult.
Interestingly, although HIV-1 production from both mono-
cytes and M/Ms infected by HIV-l1XL was decreased by
anti-FcR x anti-HIV-1 BsAbs (20 Ag/ml), at lower concen-
trations, HIV-1 production was the same as in the controls.
Moreover, in other studies using these same BsAbs, but at
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like cell line U937, ADE of HIV-1 infection was observed"*.
Although care should be taken in drawing parallels between
these two studies since the tropism and replication kinetics of
HIV-111B are markedly different in U937 cells when com-
pared to primary monocyte/macrophages, these findings
suggest that the degree of antibody opsonization is a critical
factor in determining the outcome of the HIV-1-FcyR inter-
action and that binding to either Fc'yRI or FcyRII can result
in lower infectivity. Our present data are directly relevant to,
but not inconsistent with, observations of ADE of HIV-1
infection. In particular, we propose that HIV-1 coated with
sufficient antibody will initiate high-affinity multivalent in-
teractions with FcyRs that effectively trigger endocytosis and
intracellular degradation ofthe antibody-virus complex. This
interpretation may, in fact, explain the recent observation
that increasing anti-HIV-1 titers in patients undergoing pri-
mary infection usually relate to decreased viral burden (20,
21). At lower levels of antibody opsonization, there will be
too little interaction with FcyR to initiate FcyR-mediated
endocytosis and intracellular degradation of the receptor-
virus complex but enough to enhance stability of the virus at
the cell surface, allowing infectivity to proceed through
high-affinity CD4 interactions. Bolognesi (25) has described
such a mechanism as a means of ADE of HIV-1 infection in
monocytes. This could explain, in part, why low concentra-
tions of antibody are needed for ADE of HIV-1 infection in
vitro. Consistent with this possibility, the results of our study
and those of others indicate that CD4 interaction is essential
for infectivity, even under conditions of antibody-mediated
FcyR binding.
That the magnitude ofADE ofHIV infection is far less than
with Dengue virus (25) may reflect differences in factors that
govern viral entry, including post-binding fusion events. As
with other enveloped viruses, internalization ofDengue virus
through FcyR-mediated endocytosis may allow the virus to
enter the cytoplasm through pH-dependent fusion with en-
dosomal membranes. By contrast, our studies suggest that
HIV-1 internalized through similar mechanisms may be un-
able to establish infection. This is consistent with several
studies that indicate that HIV-1 entry occurs by direct fusion
with the plasma membrane of the target cell in a manner that
is pH-independent and does not require endocytosis of the
CD4 receptor (26, 27).
The likelihood that high levels of anti-HIV-1 antibody
reduce viral infectivity through both direct and indirect
mechanisms is supported by observations from studies in-
volving vaccine trials where high titers of anti-HIV-1 anti-
body provide some protection against live virus. Also, as
indicated above, increased anti-HIV-1 antibody is related to
decreased HIV-1 titer in vivo (20, 21). Furthermore, CD16'
cells from HIV-1-seropositive individuals have been shown
to mediate killing of gpl2O-expressing targets, indicating that
antibody in conjunction with Fc receptors on effector cells
may play an important role in host defense (28).
In summary, CD4 interaction with HIV-1 appears essential
for infectivity, even under conditions of antibody-mediated
FcyR binding. Moreover, interaction of HIV-1 with FcyR
expressed on human monocytes and macrophages through
BsAbs may, under certain conditions, reduce viral infectivity
through FcyR-mediated killing mechanisms. Although fur-
ther studies are needed to define more clearly the conditions
that permit FcyRs to function as cytotoxic trigger molecules
for HIV-1, our findings suggest that BsAbs directing inter-
action of HIV-1 with FcyRs offer a potentially promising
therapeutic approach in vivo.
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